<span item_type="fundamental" item_id="bee0ea2fa0cc2bcb074ca1fef889c414" counter_id="ST/US/EOLS" env="prod"></span><span item_type="announcement" item_id="644750270043982337" env="prod"></span><p>Revenue: As of FY2026 Q1, the actual value is USD 73.14 M, beating the estimate of USD 72.17 M.</p><p>EPS: As of FY2026 Q1, the actual value is USD -0.16.</p><p>EBIT: As of FY2026 Q1, the actual value is USD -11.11 M.</p><p></p><h4>First Quarter 2026 Financial Results</h4><p>Total net revenues for the first quarter of 2026 were $73.1 million, marking a 7% increase over the first quarter of 2025. This revenue included $66.4 million from global toxin sales and $6.7 million from injectable hyaluronic acid (HA) gels.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span></p><h4>Gross Profit and Margins</h4><p>Gross profit for Q1 2026 was $48.9 million, an increase from $46.7 million in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> The gross profit margin stood at 66.9%, while the adjusted gross profit margin was 68.0%, excluding amortization of intangible assets.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span></p><h4>Operating Expenses</h4><p>GAAP operating expenses for the first quarter of 2026 were $55.7 million, an improvement from $61.8 million in the prior year period.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> Non-GAAP operating expenses were $49.1 million for Q1 2026, compared to $52.9 million in Q1 2025 and $53.0 million in Q4 2025, which included a $4.5 million benefit from a contingent royalty obligation revaluation.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span></p><h4>Operating Profit/Loss</h4><p>GAAP loss from operations significantly improved to - $6.8 million for Q1 2026, from - $15.2 million in Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> Adjusted EBITDA was $0.6 million for the first quarter of 2026, compared to a loss of - $5.5 million in the first quarter of 2025, marking the second consecutive quarter of positive Adjusted EBITDA.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> The Adjusted EBITDA margin was 0.8% for Q1 2026, up from -8.1% for Q1 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span></p><h4>Net Loss</h4><p>Net loss for the first quarter of 2026 was - $10.7 million, an improvement from - $18.9 million in the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span></p><h4>Cash Flow and Balance Sheet</h4><p>Net cash used in operating activities was - $9.9 million for the three months ended March 31, 2026, compared to - $15.6 million for the same period in 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> Net cash used in investing activities was - $1.7 million, and net cash provided by financing activities was $7.6 million for the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> As of March 31, 2026, Evolus, Inc. held cash and cash equivalents of $49.8 million, down from $53.8 million on December 30, 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> Total assets were $220.6 million, and total liabilities were $249.4 million as of March 31, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> Total stockholders’ equity (deficit) was - $28.8 million, and long-term debt stood at $156.4 million as of March 31, 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span></p><h4>Operational Metrics and Highlights</h4><p>Total purchasing accounts increased by nearly 500 in the first quarter of 2026.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> Since its launch, over 18,100 customers have purchased from Evolus, Inc., with approximately 3,500 purchasing Evolysse®, which has driven U.S. account penetration above 60%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> Customer reorder rates are approximately 71%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> Members in the Evolus Rewards™ consumer loyalty program grew by nearly 75,000 during the quarter to approach 1.5 million, representing a 27% increase compared to the first quarter of 2025.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> Total Evolus Rewards™ redemptions reached an all-time high of over 255,000, with existing patients receiving repeat treatments at approximately 70%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span></p><h4>Capital Markets Activity</h4><p>Evolus, Inc. terminated a Sales Agreement on May 1, 2026, which had allowed for the offer and sale of up to $50.0 million of its common stock through “at-the-market” offerings; no shares were sold under this agreement prior to its termination.<span class="superscript" item_id="0" item_type="announcement_file" value="2" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/eols-20260504.htm"></span></p><h4>Outlook and Guidance</h4><p>Evolus, Inc. reaffirms its full-year 2026 net revenue guidance of $327 million to $337 million, projecting 10% to 13% growth over the prior year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> The company expects full-year 2026 non-GAAP operating expenses to range between $210 million and $216 million, anticipating a low- to mid-single digit Adjusted EBITDA margin for the year.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span> For 2028, Evolus, Inc. projects total net revenue between $450 million and $500 million, with Adjusted EBITDA margins expected to be 13% to 15%.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1570562/000157056226000064/q12026eolsex991.htm"></span></p>

Evolus | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 73.14 M